Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies Involved in Therapeutics Development Addex Therapeutics Ltd Bristol-Myers Squibb Co Camino Pharma LLC Denovo Biopharma LLC Eli Lilly and Co Johnson & Johnson Mediti Pharma Inc Merck & Co Inc Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles ADX-92639 - Drug Profile Product Description Mechanism Of Action R&D Progress BMT-133218 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-40411813 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-5515 - Drug Profile Product Description Mechanism Of Action R&D Progress LY-3020371 - Drug Profile Product Description Mechanism Of Action R&D Progress LY-341495 - Drug Profile Product Description Mechanism Of Action R&D Progress MP-101 - Drug Profile Product Description Mechanism Of Action R&D Progress pomaglumetad methionil - Drug Profile Product Description Mechanism Of Action R&D Progress SBP-0069330 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Products Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Product Development Milestones Featured News & Press Releases Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy Sep 04, 2018: Addex’s selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer’s Disease Model Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indication, H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Number of Products under Investigation by Universities/Institutes, H1 2019 Products under Investigation by Universities/Institutes, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by Addex Therapeutics Ltd, H1 2019 Pipeline by Bristol-Myers Squibb Co, H1 2019 Pipeline by Camino Pharma LLC, H1 2019 Pipeline by Denovo Biopharma LLC, H1 2019 Pipeline by Eli Lilly and Co, H1 2019 Pipeline by Johnson & Johnson, H1 2019 Pipeline by Mediti Pharma Inc, H1 2019 Pipeline by Merck & Co Inc, H1 2019 Dormant Products, H1 2019 Dormant Products, H1 2019 (Contd..1), H1 2019 Dormant Products, H1 2019 (Contd..2), H1 2019 Discontinued Products, H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019

Addex Therapeutics Ltd Bristol-Myers Squibb Co Camino Pharma LLC Denovo Biopharma LLC Eli Lilly and Co Johnson & Johnson Mediti Pharma Inc Merck & Co Inc